Physician profile
Sierra L Roach
NPI 1275289894
$6,009.17
in general payments reported to CMS, 2019-2025
12 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,938 · 2023: $1,681 · 2024: $985 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614 · Travel and Lodging: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.57 |
| Travel and Lodging | $1,458.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,791.93 | 2022-2025 | Infinity, Eterna, Proclaim |
| Abbvie INC. | $302.86 | 2023-2025 | |
| Averitas Pharma INC. | $133.89 | 2023-2025 | Qutenza |
| Emd Serono, INC. | $132.80 | 2025 | |
| Neurocrine Biosciences, INC. | $127.33 | 2025 | |
| Eisai INC. | $116.59 | 2024 | |
| Amgen INC. | $111.35 | 2025 | |
| Sanofi-Aventis U.S. LLC | $106.56 | 2025 | |
| Jazz Pharmaceuticals INC. | $95.60 | 2025 | |
| Curonix LLC | $60.54 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pfizer INC. | $16.74 | 2024 | |
| Alexion Pharmaceuticals, INC. | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sierra Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.